Loading stock…

Pediatrix Medical Group, Inc. (MD) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Pediatrix Medical Group, Inc.

MDMarket cap $2.06BPrice $26.0

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

Provides neonatal, maternal-fetal, and pediatric subspecialty care through physician groups staffing hospitals nationwide. It's one of the largest providers of newborn intensive care in the U.S., often stepping in during a baby's most fragile first hours.

In Bastion Portfolios?

52W Return+58%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-1%3

Revenue Forecast

Rev CAGR (1y)+2%3

Rev CAGR (3y)+3%3

Rev CAGR (5y)+4%3

Earnings Forecast

EPS Growth Y+1+20%8

EPS Growth Y+2+2%4

EPS Growth Y+3-0%3

Quality

Margins

EBIT Margin12%5

Net Income Margin9%5

Free Cash Flow Margin12%6

Debt

Net Debt/EBITDA0.86

Efficiency

ROE20%8

ROA8%8

Earnings Stability44

GEAR+AVERAGE50

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)118

P/E Ratio (Forward 3y)117

P/BV2.36

EV Multiples

EV/EBITDA Fwd88

EV/EBIT Fwd99

Yield

Free Cash Flow Yield11.1%9

Dividend Yieldna–

Momentum

Short term

1 month return-4%6

3 month return-3%5

YTD return+22%8

Mid term

Price vs 52wHigh93%9

1 year return+48%9

Long term

3 year return+102%7

5 year return-5%3

Risk Shield

Price Risk

Beta0.67

Volatility41%4

Free Cash Flow

Free Cash Flow Margin12%6

Free Cash Flow Yield11.1%9

Quality

ROCE14%7

Earnings Stability44

Net Debt/EBITDA0.86

02Growth

Is it actually growing, and how fast?

MDPediatrix Medical Group

Revenue FY25$1.9B

GROWTH RATING↗

WEAK20 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-1%3

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+3%3

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+20%8

EPS growth, FY27E+2%4

EPS growth, FY28E-0%3

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

After shrinking over the last 3 years, revenue is set to grow 3%/yr from here.

Earnings are set to grow in step with sales (EPS about 2%/yr vs revenue 3%/yr).

WEAKNESSES

Growth is the weak spot here, trailing 80% of companies worldwide.

Revenue fell 1%/yr over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG67 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return-3%5

YTD return+22%8

MID & LONG-TERM▾SCORE

% of 52-week high93%9

1-year return+48%9

3-year return+102%7

5-year return-5%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 48% over the past year, now 7% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+22%).

WATCH

Average long-term results. Multi-year returns are middling (+102% over three years and -5.2% over five), roughly average for the market.

Returns sit at the market level over the past month (-4%) and over three months (-3%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Pediatrix Medical Group, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

MDPediatrix Medical Group

Revenue FY25$1.9B

GROWTH RATING↗

WEAK20 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-1%3

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+3%3

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+20%8

EPS growth, FY27E+2%4

EPS growth, FY28E-0%3

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

After shrinking over the last 3 years, revenue is set to grow 3%/yr from here.

Earnings are set to grow in step with sales (EPS about 2%/yr vs revenue 3%/yr).

WEAKNESSES

Growth is the weak spot here, trailing 80% of companies worldwide.

Revenue fell 1%/yr over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG67 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return-3%5

YTD return+22%8

MID & LONG-TERM▾SCORE

% of 52-week high93%9

1-year return+48%9

3-year return+102%7

5-year return-5%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 48% over the past year, now 7% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+22%).

WATCH

Average long-term results. Multi-year returns are middling (+102% over three years and -5.2% over five), roughly average for the market.

Returns sit at the market level over the past month (-4%) and over three months (-3%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Pediatrix Medical Group, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community